Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.

Journal of virological methods - 1 Oct 2013

O'Boyle Donald R, Nower Peter T, Sun Jin-Hua, Fridell Robert, Wang Chunfu, Valera Lourdes, Gao Min

Abstract excerpt

A 96-well based replicon elimination and colony formation assay is presented for comparing the resistance barrier of the hepatitis C virus (HCV) NS5A replication complex inhibitor daclatasvir (DCV, BMS-790052) on three HCV genotypes (gts) in a proof of concept experimental protocol. The 96-well assay format provides both individual colony as well as population characterization and is readily applicable to other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Luciferases

Share to Pyrrolidines

Share to Staining and Labeling

Share to Valine

Share to Virology

Source

Identifiers

PMID: 23684844
DOI: 10.1016/j.jviromet.2013.04.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.PMID 23684844Read ↗

Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.Semantic proximity Read ↗

Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals.Semantic proximity Read ↗

Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.Semantic proximity Read ↗

Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines.Semantic proximity Read ↗

HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.Semantic proximity Read ↗

Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.Semantic proximity Read ↗

Discovery and Development of Hepatitis C Virus NS5A Replication Complex InhibitorsSemantic proximity Read ↗

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Semantic proximity Read ↗

Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.Semantic proximity Read ↗

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.Semantic proximity Read ↗

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.Semantic proximity Read ↗

Studies on hepatitis C virus resistance to inhibitors in replicon systems.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.